Alnylam Surges Ahead of Peers, Beats Earnings, and Boosts Nasdaq Shares
Alnylam’s latest earnings beat the market, propelling it past peers like Regeneron and Lilly and underscoring its RNA‑silencing pipeline’s upside for investors.
2 minutes to read
